142 related articles for article (PubMed ID: 21717091)
1. Safety and feasibility of S-1 adjuvant chemotherapy for gastric cancer in elderly patients.
Aoyama T; Yoshikawa T; Watanabe T; Hayashi T; Ogata T; Cho H; Tsuburaya A
Gastric Cancer; 2012 Jan; 15(1):76-82. PubMed ID: 21717091
[TBL] [Abstract][Full Text] [Related]
2. Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients.
Aoyama T; Katayama Y; Murakawa M; Atsumi Y; Yamaoku K; Kanazawa A; Higuchi A; Shiozawa M; Kobayashi S; Ueno M; Morimoto M; Yamamoto N; Oshima T; Yoshikawa T; Rino Y; Masuda M; Morinaga S
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1115-20. PubMed ID: 25821166
[TBL] [Abstract][Full Text] [Related]
3. Feasibility study of alternate-day S-1 as adjuvant chemotherapy for gastric cancer: a randomized controlled trial.
Tatebe S; Tsujitani S; Nakamura S; Shimizu T; Yamane N; Nishidoi H; Kurisu Y; Kanayama H; Ogawa H; Ikeguchi M
Gastric Cancer; 2014; 17(3):508-13. PubMed ID: 23948997
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer.
Tsushima T; Hironaka S; Boku N; Machida N; Yamazaki K; Yasui H; Taku K; Fukutomi A; Onozawa Y
Gastric Cancer; 2010 Nov; 13(4):245-50. PubMed ID: 21128060
[TBL] [Abstract][Full Text] [Related]
5. Risk Factors for Poor Compliance with Adjuvant S-1 Chemotherapy for Gastric Cancer: A Multicenter Retrospective Study.
Yamashita K; Kurokawa Y; Yamamoto K; Hirota M; Kawabata R; Mikami J; Masuzawa T; Takiguchi S; Mori M; Doki Y
Ann Surg Oncol; 2017 Sep; 24(9):2639-2645. PubMed ID: 28608116
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
[TBL] [Abstract][Full Text] [Related]
7. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
Ito S; Ohashi Y; Sasako M
BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
[TBL] [Abstract][Full Text] [Related]
8. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.
Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Yamada T; Tsuchida K; Hasegawa S; Cho H; Yukawa N; Oshima T; Rino Y; Masuda M; Tsuburaya A
Ann Surg Oncol; 2013 Jun; 20(6):2000-6. PubMed ID: 23242818
[TBL] [Abstract][Full Text] [Related]
9. Feasibility study of S-1 for resectable gastric cancer with peritoneal seeding.
Fujitani K; Tsujinaka T; Hirao M
Hepatogastroenterology; 2003; 50(51):889-92. PubMed ID: 12828112
[TBL] [Abstract][Full Text] [Related]
10. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.
Kinoshita T; Nashimoto A; Yamamura Y; Okamura T; Sasako M; Sakamoto J; Kojima H; Hiratsuka M; Arai K; Sairenji M; Fukushima N; Kimura H; Nakajima T
Gastric Cancer; 2004; 7(2):104-9. PubMed ID: 15224197
[TBL] [Abstract][Full Text] [Related]
11. A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703).
Kodera Y; Ishiyama A; Yoshikawa T; Kinoshita T; Ito S; Yokoyama H; Mochizuki Y; Ito H; Tsuburaya A; Sakamoto J; Nakao A;
Gastric Cancer; 2010 Aug; 13(3):197-203. PubMed ID: 20820990
[TBL] [Abstract][Full Text] [Related]
12. [Effect of Post-Gastrectomy Adjuvant S-1 Chemotherapy on Muscle Volume in Gastric Cancer Patients].
Iwazawa T; Kawanishi K; Fujita J; Takata A; Hirota M; Imamura H; Ikeda A; Hokonohara K; Yoneyama C; Kameyama A; Shinke G; Oshima K; Tanida T; Hatano H; Noda T; Komori T; Morita S; Akagi K; Dono K
Gan To Kagaku Ryoho; 2015 Aug; 42(8):957-60. PubMed ID: 26321709
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer.
Aoyama T; Katayama Y; Murakawa M; Asari M; Kanazawa A; Higuchi A; Shiozawa M; Kobayashi S; Ueno M; Morimoto M; Ohkawa S; Akaike M; Yamamoto N; Yoshikawa T; Rino Y; Masuda M; Morinaga S
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1235-40. PubMed ID: 25297990
[TBL] [Abstract][Full Text] [Related]
14. Questionnaire survey on adjuvant chemotherapy for elderly patients after gastrectomy indicates their vulnelabilities.
Tanahashi T; Yoshida K; Yamaguchi K; Okumura N; Takeno A; Fujitani K; Fukushima N; Takiguchi N; Nishida Y; Boku N; Yoshikawa T; Terashima M
Gastric Cancer; 2019 Jan; 22(1):130-137. PubMed ID: 29799059
[TBL] [Abstract][Full Text] [Related]
15. Safety, compliance, and predictive parameters for dosage modification in adjuvant S-1 chemotherapy for gastric cancer.
Kim SJ; Kim YJ; Kim JH; Park DJ; Kim HH; Lee JS; Lee KW
Cancer Sci; 2013 Jan; 104(1):116-23. PubMed ID: 23066919
[TBL] [Abstract][Full Text] [Related]
16. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
Kanda M; Murotani K; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Surgery; 2015 Dec; 158(6):1573-80. PubMed ID: 26120068
[TBL] [Abstract][Full Text] [Related]
17. Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Tsuda Y; Shoji Y; Yasufuku I; Eto K; Ida S; Kumagai K; Nunobe S; Sano T
Gastric Cancer; 2018 Nov; 21(6):1024-1030. PubMed ID: 29700635
[TBL] [Abstract][Full Text] [Related]
18. The role of S-1 in the treatment of gastric cancer.
Kubota T
Br J Cancer; 2008 Apr; 98(8):1301-4. PubMed ID: 18362933
[TBL] [Abstract][Full Text] [Related]
19. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial.
Yoshikawa T; Terashima M; Mizusawa J; Nunobe S; Nishida Y; Yamada T; Kaji M; Fukushima N; Hato S; Choda Y; Yabusaki H; Yoshida K; Ito S; Takeno A; Yasuda T; Kawachi Y; Katayama H; Fukuda H; Boku N; Sano T; Sasako M
Lancet Gastroenterol Hepatol; 2019 Mar; 4(3):208-216. PubMed ID: 30679107
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer.
Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A
Gastric Cancer; 2013 Apr; 16(2):133-9. PubMed ID: 22527186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
